Automatized "Semi-Whole-Body"-MRI Protocol for Cancer Staging

Kantonsspital Baden

Status: Terminated

Conditions: Oncology

Treatments: Diagnostic Test: Semi whole-body MRI

Study type: Interventional

Funder types: Other

Identifiers

NCT03648619

2017-00964

Details and patient eligibility

About

The aims of this study are

• to evaluate the image quality and robustness of a whole-body MRI protocol by using an innovative partially automatic algorithm (DOT engine), that automatically optimizes protocol parameters depending on body region (e.g. thorax versus abdomen)
• to compare lesion detectability between wb-MRI and the gold standard positron emission tomography (PET)/CT
• to compare patient comfort between PET/CT and wb-MRI using a dedicated questionnaire
• to compare duration of image acquisition with regards to cost-effectiveness

Full description

Whole-body imaging becomes increasingly important in oncologic patients not only for primary cancer staging, but also for assessment of response to therapy. So far, PET/CT is a key method to assess cancer-related changes of metabolism in tumors, which is crucial for response evaluation and to differentiate between benign and malignant lesions. Limitations of PET/CT include the assessment of sclerotic bone metastasis, which often do not show increased tracer uptake. Certain organ metastasis (especially in brain and liver) are also barely detectable due to physiologically increased uptake. Moreover, both CT and administration of radioactive tracer are associated with radiation exposure for patients. Whole-body MRI (wb-MRI) including functional techniques (e.g. Diffusion-weighted Imaging (DWI) to evaluate cell density) enables a functional staging and therapy assessment without use of ionizing radiation. Advantages to assess sclerotic bone lesions and organ metastases have been confirmed in recent literature. Limitations of MRI include detection of lesions in organs with high susceptibility and motion like the thorax.

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinically indicated PET/CT for cancer staging or response assess-ment in patients with histopathologically confirmed solid tumors (e.g.prostate, breast, gastrointestinal, testicles)
• MRI can be scheduled within 1 week to PET/CT exam

Exclusion criteria

• general MRI contraindications (devices (e.g. certain pacemakers), pregnancy, claustrophobia)
• severely reduced general condition
• impaired renal function

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Oncologic patients

Other group

Description:

Oncologic patients with a previous PET/CT for whole-body staging

Treatment:

Diagnostic Test: Semi whole-body MRI